0
New
New
2023
Diabetic Nephropathy Market

Diabetic nephropathy Market

by Drugs Class (Angiotensin-converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blocker, Diuretics, Renin Inhibitor, Others), by Type (Type-1 Diabetes, Type-2 Diabetes), by Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2022-2031

Report Code: A16604
Aug 2023 | Pages: 266
Tables: 128
Charts: 61
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Diabetic Nephropathy Market Research, 2031

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.

Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It occurs when high blood glucose levels damages kidney functions. It can occur in people with type-2 diabetes. Diabetic nephropathy is caused by damage to the tiniest blood vessels. When small blood vessels begin to develop damage, both kidneys begin to leak proteins into the urine. As damage to the blood vessels continues, the kidneys gradually lose their ability to remove waste products from the blood. It occurs when high blood glucose levels damage kidney function. Up to 40% of people with type-1 diabetes eventually develop significant kidney diseases, which sometimes requires dialysis or a kidney transplant. Only 4 to 6 % of all type-2 diabetes patients end up requiring dialysis, although about 20–30% of people with type-2 diabetes develop at least some kidney damage. About 40% of all people who need to start dialysis have kidney failure from type-1 or type-2 diabetes.

The diabetic nephropathy is diagnosed by different test such as urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR), and other special tests includes imaging tests (CT scanning, MRI) and Kidney biopsy.

The COVID-19 outbreak is anticipated to have a negative impact on the diabetic nephropathy Market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 epidemic had a negative impact on the diabetic nephropathy market because priority is given to COVID-19 patient for treatment. Discovery and development of diabetic nephropathy medicine is slowing down during pandemic but did not stop

Diabetic nephropathy Market

The major factors that drive the diabetic nephropathy market is surge in number of geriatric populations suffering from diabetic nephropathy, continuous increase in range of conditions that can be treated by diabetic nephropathy medicine and rise in demand of anti-diabetic medicine. This market also increased due to rise in incidence rates of various kidney diseases and rise in testing, which are expected to offer lucrative opportunities for market expansion.

Diabetic nephropathy can be controlled by taking medication, low protein diet, adopt healthy lifestyle, exercise and proper checkup that are preventing from kidney failure. Furthermore, diabetic nephropathy medicine work by controlling the blood glucose level, lowering cholesterol level and lowering to high blood pressure (hypertension). Due to wide application of diabetic nephropathy medicine and increasing the diagnostic tests of diabetic nephropathy are led to the growth of diabetic nephropathy market share. Moreover, increase in initiatives by governments & non-governmental organizations to promote awareness about diabetic nephropathy significantly contributes toward the growth of the industry.

However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to lack of skilled professionals for treatment of diabetic nephropathy in emerging and less developed countries, poor planning of diabetic nephropathy treatment in low-income countries are the key factors restraining the market. Strict regulatory rules regarding selling and lengthy approval time for drugs for diabetic nephropathy are also hamper the market growth. Due to these factors, the sales of premium diabetic nephropathy product are minimum. Conversely, the introduction of new medicine of diabetic nephropathy into developing nations is anticipated to offer remunerative opportunities for the expansion of the global market during the forecast period.

Furthermore, the healthcare business in developing nations is predicted to grow significantly as a result of various reasons, including increased investment in both the public and private sectors, rise in chronic diseases, surge in number of diabetes cases, and population expansion. Furthermore, an increase in healthcare spending is expected to promote the expansion of the healthcare business, which, in turn, is expected to fuel product demand.

The significant reduction in clinical trials due to strict government guidelines against COVID-19. Dialysis and transplant of kidney operation in diabetic nephropathy patient were postponed and home care setting care was preferred. Furthermore, the lockdown led to the disruption of manufacturing and transportation of healthcare essentials. According to FDA data that was published in 2019, approximately 40% pharmaceutical manufacturing unit established in India and China for the active pharmaceutical ingredient. Therefore, it has severely impacted to the supply chain of drugs.

The diabetic nephropathy market is segmented into Drugs Class, Type and Distribution Channel.

 On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor and others. By type, the market is segregated into type-1 diabetes, & type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug & retail pharmacy.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Segment Review

Depending on drug class, in diabetic nephropathy market size, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor in the global market in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.

Diabetic nephropathy Market
By Drugs Class

Your browser does not support the canvas element.

Diuretics segment was the leading segment during forecast period.

Get more information on this report : Request Sample Pages

On the basis of type of diabetic nephropathy, the type-2 diabetes segment generated maximum revenue in 2021, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR during the diabetic nephropathy market forecast period.

Diabetic nephropathy Market
By Type

Your browser does not support the canvas element.

Type-2 Diabetes segment dominates the South Africa Diabetic nephropathy Market and is expected to retain its dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

On the basis of distribution channel, in diabetic nephropathy market size, the drug stores & retail pharmacy segment was the highest revenue contributor to the market in 2021. The online providers segment is expected to witness highest CAGR during the forecast period, owing to increase in population suffering from diabetes and geriatric population.

Diabetic nephropathy Market
By Distribution Channel

Your browser does not support the canvas element.

Online Providers segment is projected to be the dominating segment throughout the forecast period.

Get more information on this report : Request Sample Pages

Depending on region, the North America generated maximum revenue in 2021, owing to increase in the number of patient admissions, and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.

Diabetic nephropathy Market
By Region

2031
North America 
Europe
Asia-Pacific
LAMEA

North America held the largest market share in 2021

Get more information on this report : Request Sample Pages

The key players operating in the diabetic nephropathy industry are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and diabetic nephropathy market growth strategies.

Diabetic nephropathy Market Report Highlights

Aspects Details
Market Size By 2031 USD 3.3 billion
Growth Rate CAGR of 6%
Forecast period 2021 - 2031
Report Pages 266
By Distribution Channel
  • Hospital Pharmacy
  • Online Providers
  • Drug Stores and Retail Pharmacy
By Drugs Class
  • Angiotensin-converting Enzyme Inhibitors
  • Angiotensin Receptor Blockers
  • Calcium Channel Blocker
  • Diuretics
  • Renin Inhibitor
  • Others
By Type
  • Type-1 Diabetes
  • Type-2 Diabetes
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Pfizer Inc., Astrazenica Plc, Novartis AG, Bayer AG, Abbott Laboratories, AbbVie Inc., Sanofi, Reata Pharmaceuticals, Merck & Co, Eli Lilly and Company

Analyst Review

This section provides opinions of top level CXOs in the diabetic nephropathy market. According to insights of CXOs, diabetic nephropathy is gaining high traction in the market, owing to increase in prevalence of diabetes and obesity, rise in R&D investments in drug discovery & development, and increase in awareness regarding diabetes & kidney-related disorders. Furthermore, key players in the market are focusing on adopting strategies to increase accessibility and utilization of diabetic nephropathy products in developing economies.

CXOs further added that diabetic nephropathy medicines provide relief from inflammation and help in lowering blood glucose level and preventing from chronic renal disease. Anti-diabetic nephropathy medicine is also lower to cholesterol level and maintaining blood pressure. Furthermore, experts of key companies believe surge in geriatric population, which is more prone to diabetic nephropathy diseases that require advanced treatment such as dialysis and transplant and rise in cases of diabetic nephropathy in adults may require temporary or permanent diabetic nephropathy treatment, thus increasing utilization of medicines. The market gains interest of healthcare companies, owing to its unmet demands in developing economies such as India and China where the population is growing rapidly along with diabetes load.

North America is expected to witness highest growth, in terms of revenue, owing to increase in cases of diabetes, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, unmet medical demands, initiatives by government & non-governmental organizations (NGOs) to promote awareness regarding diabetic nephropathy, and increase in public–private investments in the healthcare sector

 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension
        • 3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests

      • 3.4.2. Restraints

        • 3.4.2.1. Strict regulatory rules and lengthy drug approval times

      • 3.4.3. Opportunities

        • 3.4.3.1. Rise in use of combination therapy for diabetic nephropathy
        • 3.4.3.2. Increase in R&D investments in drug discovery and development

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Angiotensin-converting Enzyme Inhibitors

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Angiotensin Receptor Blockers

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Calcium Channel Blocker

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

    • 4.5. Diuretics

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast, by region

      • 4.5.3. Market share analysis by country

    • 4.6. Renin Inhibitor

      • 4.6.1. Key market trends, growth factors and opportunities

      • 4.6.2. Market size and forecast, by region

      • 4.6.3. Market share analysis by country

    • 4.7. Others

      • 4.7.1. Key market trends, growth factors and opportunities

      • 4.7.2. Market size and forecast, by region

      • 4.7.3. Market share analysis by country

  • CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Type-1 Diabetes

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Type-2 Diabetes

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

  • CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Online Providers

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Drug Stores and Retail Pharmacy

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

  • CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Drugs Class

      • 7.2.3. Market size and forecast, by Type

      • 7.2.4. Market size and forecast, by Distribution Channel

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Drugs Class
          • 7.2.5.1.3. Market size and forecast, by Type
          • 7.2.5.1.4. Market size and forecast, by Distribution Channel
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Drugs Class
          • 7.2.5.2.3. Market size and forecast, by Type
          • 7.2.5.2.4. Market size and forecast, by Distribution Channel
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Drugs Class
          • 7.2.5.3.3. Market size and forecast, by Type
          • 7.2.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Drugs Class

      • 7.3.3. Market size and forecast, by Type

      • 7.3.4. Market size and forecast, by Distribution Channel

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Drugs Class
          • 7.3.5.1.3. Market size and forecast, by Type
          • 7.3.5.1.4. Market size and forecast, by Distribution Channel
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Drugs Class
          • 7.3.5.2.3. Market size and forecast, by Type
          • 7.3.5.2.4. Market size and forecast, by Distribution Channel
        • 7.3.5.3. U.K.
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Drugs Class
          • 7.3.5.3.3. Market size and forecast, by Type
          • 7.3.5.3.4. Market size and forecast, by Distribution Channel
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Drugs Class
          • 7.3.5.4.3. Market size and forecast, by Type
          • 7.3.5.4.4. Market size and forecast, by Distribution Channel
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Drugs Class
          • 7.3.5.5.3. Market size and forecast, by Type
          • 7.3.5.5.4. Market size and forecast, by Distribution Channel
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Drugs Class
          • 7.3.5.6.3. Market size and forecast, by Type
          • 7.3.5.6.4. Market size and forecast, by Distribution Channel
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Drugs Class

      • 7.4.3. Market size and forecast, by Type

      • 7.4.4. Market size and forecast, by Distribution Channel

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Drugs Class
          • 7.4.5.1.3. Market size and forecast, by Type
          • 7.4.5.1.4. Market size and forecast, by Distribution Channel
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Drugs Class
          • 7.4.5.2.3. Market size and forecast, by Type
          • 7.4.5.2.4. Market size and forecast, by Distribution Channel
        • 7.4.5.3. Australia
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Drugs Class
          • 7.4.5.3.3. Market size and forecast, by Type
          • 7.4.5.3.4. Market size and forecast, by Distribution Channel
        • 7.4.5.4. India
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Drugs Class
          • 7.4.5.4.3. Market size and forecast, by Type
          • 7.4.5.4.4. Market size and forecast, by Distribution Channel
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Drugs Class
          • 7.4.5.5.3. Market size and forecast, by Type
          • 7.4.5.5.4. Market size and forecast, by Distribution Channel
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Drugs Class
          • 7.4.5.6.3. Market size and forecast, by Type
          • 7.4.5.6.4. Market size and forecast, by Distribution Channel
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Drugs Class

      • 7.5.3. Market size and forecast, by Type

      • 7.5.4. Market size and forecast, by Distribution Channel

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Drugs Class
          • 7.5.5.1.3. Market size and forecast, by Type
          • 7.5.5.1.4. Market size and forecast, by Distribution Channel
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Drugs Class
          • 7.5.5.2.3. Market size and forecast, by Type
          • 7.5.5.2.4. Market size and forecast, by Distribution Channel
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Drugs Class
          • 7.5.5.3.3. Market size and forecast, by Type
          • 7.5.5.3.4. Market size and forecast, by Distribution Channel
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Drugs Class
          • 7.5.5.4.3. Market size and forecast, by Type
          • 7.5.5.4.4. Market size and forecast, by Distribution Channel
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. AbbVie Inc.

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

    • 9.2. Abbott Laboratories

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Business performance

    • 9.3. Bayer AG

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

    • 9.4. Eli Lilly and Company

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

    • 9.5. Merck & Co

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

    • 9.6. Astrazenica Plc

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

    • 9.7. Novartis AG

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

    • 9.8. Pfizer Inc.

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. Reata Pharmaceuticals

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Sanofi

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

  • LIST OF TABLES

  • TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)
    TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)
    TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)
    TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
    TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
    TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 89. ABBVIE INC.: KEY EXECUTIVES
    TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT
    TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS
    TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO
    TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
    TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
    TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS
    TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 97. BAYER AG: KEY EXECUTIVES
    TABLE 98. BAYER AG: COMPANY SNAPSHOT
    TABLE 99. BAYER AG: PRODUCT SEGMENTS
    TABLE 100. BAYER AG: PRODUCT PORTFOLIO
    TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
    TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
    TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 105. MERCK & CO: KEY EXECUTIVES
    TABLE 106. MERCK & CO: COMPANY SNAPSHOT
    TABLE 107. MERCK & CO: PRODUCT SEGMENTS
    TABLE 108. MERCK & CO: PRODUCT PORTFOLIO
    TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES
    TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT
    TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS
    TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO
    TABLE 113. NOVARTIS AG: KEY EXECUTIVES
    TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
    TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 117. PFIZER INC.: KEY EXECUTIVES
    TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
    TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
    TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
    TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES
    TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS
    TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 125. SANOFI: KEY EXECUTIVES
    TABLE 126. SANOFI: COMPANY SNAPSHOT
    TABLE 127. SANOFI: PRODUCT SEGMENTS
    TABLE 128. SANOFI: PRODUCT PORTFOLIO
  • LIST OF FIGURES

  • FIGURE 1.DIABETIC NEPHROPATHY MARKET SEGMENTATION
    FIGURE 2.DIABETIC NEPHROPATHY MARKET,2021-2031
    FIGURE 3.DIABETIC NEPHROPATHY MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.DIABETIC NEPHROPATHY MARKET,BY DRUGS CLASS,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANGIOTENSIN RECEPTOR BLOCKERS DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKER DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF DIURETICS DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF RENIN INHIBITOR DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 19.DIABETIC NEPHROPATHY MARKET,BY TYPE,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF TYPE-1 DIABETES DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TYPE-2 DIABETES DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 22.DIABETIC NEPHROPATHY MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACY DIABETIC NEPHROPATHY MARKET,2021-2031(%)
    FIGURE 26.DIABETIC NEPHROPATHY MARKET BY REGION,2021
    FIGURE 27.U.S. DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 28.CANADA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 29.MEXICO DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 30.GERMANY DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 31.FRANCE DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 32.U.K. DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 33.ITALY DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 34.SPAIN DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 35.REST OF EUROPE DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 36.JAPAN DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 37.CHINA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 38.AUSTRALIA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 39.INDIA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 40.SOUTH KOREA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 41.REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 42.BRAZIL DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 43.SAUDI ARABIA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 44.SOUTH AFRICA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 45.REST OF LAMEA DIABETIC NEPHROPATHY MARKET,2021-2031($MILLION)
    FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 50.COMPETITIVE DASHBOARD
    FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
    FIGURE 53.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
    FIGURE 54.BAYER AG.: NET SALES ,($MILLION)
    FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
    FIGURE 56.MERCK & CO.: NET SALES ,($MILLION)
    FIGURE 57.ASTRAZENICA PLC.: NET SALES ,($MILLION)
    FIGURE 58.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 59.PFIZER INC..: NET SALES ,($MILLION)
    FIGURE 60.REATA PHARMACEUTICALS.: NET SALES ,($MILLION)
    FIGURE 61.SANOFI.: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of Diabetic Nephropathy is $3,338.5 million in 2031.

A. Top companies such as Abbott Laboratories, AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc.. held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in U.S., Europe and LAMEA.

A. The diuretics segment is the most influencing segment owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.

A. The forecast period for Diabetic Nephropathy is 2022 to 2031.

A. The market value of Diabetic Nephropathy in 2021 is $1,863.17 million.

A. Yes, the Diabetic Nephropathy report provides PORTER Analysis.

A. The base year is 2021 in Diabetic Nephropathy.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Diabetic Nephropathy Market

Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers